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ABSTRACT
Introduction: The emergence, spread and per-
sistence of methicillin-resistant Staphylococcus
aureus (MRSA) as a causative pathogen in com-
munity-onset (CO) skin and soft tissue infec-
tions (SSTIs) have resulted in substantial
changes in the management of these infections.
The indications for obtaining blood cultures in
patients with CO-MRSA SSTIs remain poorly
defined. The objectives of this study were to
derive and validate a clinical decision rule that
predicts the probability of MRSA bacteremia in
CO-MRSA SSTIs and to identify a low-risk
population for whom blood cultures may be
safely omitted.
Methods: This was a retrospective, case-control
study with an internal temporal validation
cohort conducted at two large urban academic
medical centers. Hospitalized adults with CO-
MRSA SSTI between 2010 and 2018 were inclu-
ded. Independent predictors of MRSA bac-
teremia were identified through multivariable
logistic regression. A decision rule was derived
using weighted coefficient-based scoring. The
decision rule was validated in an internal tem-
poral validation cohort.
Results: A total of 307 patients (155 cases and
152 controls) were included in the derivation
cohort. A decision rule was created with a
‘‘major criterion’’ defined as purulent cellulitis
and ‘‘minor criteria’’ defined as abnormal tem-
perature, intravenous drug use, leukocytosis,
tachycardia, body mass index \ 25 kg/m2 and
non-upper extremity infection site. A blood
culture is indicated by this rule for patients with
one major or at least two minor criteria.
Otherwise patients are classified as low risk, and
blood cultures may be omitted. The sensitivity
of the decision rule in the derivation and vali-
dation cohorts was 98.71% (95% CI 95.42%,
99.84%) and 95.65% (78.05%, 99.89%), respec-
tively. The specificity was 23.03% (95% CI
16.59%, 30.54%) and 30.77% (95% CI 24.15%,
38.02%), respectively.
Conclusion: The decision rule developed and
validated in this study provides a standardized,
Enhanced Digital Features To view enhanced digital
features for this article go to https://doi.org/10.6084/
m9.figshare.7674074.
S. C. J. Jorgensen  A. M. Lagnf  S. Bhatia 
N. B. Singh  L. K. Shammout  S. L. Davis 
M. J. Rybak (&)
Anti-Infective Research Laboratory, College of
Pharmacy and Health Sciences, Wayne State
University, Detroit, MI, USA
e-mail: m.rybak@wayne.edu
S. L. Davis
Department of Pharmacy, Henry Ford Hospital,
Detroit, MI, USA
M. J. Rybak
Department of Pharmacy, Detroit Medical Center,
Detroit, MI, USA
M. J. Rybak
School of Medicine, Wayne State University,
Detroit, MI, USA
Infect Dis Ther (2019) 8:229–242
https://doi.org/10.1007/s40121-019-0238-1
evidenced-based approach to determine the
need for blood cultures based on bacteremia risk.
Keywords: Bloodstream infection; Methicillin-
resistant Staphylococcus aureus; Skin and soft
tissue infection
INTRODUCTION
Skin and soft tissue infections (SSTIs) are among
the most common infections encountered in
both the ambulatory and inpatient settings and
are associated with significant clinical and eco-
nomic burdens [1, 2]. The emergence, spread
and persistence of methicillin-resistant Staphy-
lococcus aureus (MRSA) as a causative pathogen
in community-onset (CO) SSTI have resulted in
substantial changes to the epidemiology and
management of these infections [1, 3, 4]. The
changing etiology of CO-SSTIs coincided with
dramatic increases in MRSA-related hospital-
izations during the first decade of this century
[5]. Although bacteremia has traditionally been
considered a relatively rare complication of
SSTI, recent evidence suggests that the MRSA
USA300 clone may have an enhanced propen-
sity to cause invasive disease, and blood culture
positivity rates of 10% to 18% have been doc-
umented among hospitalized SSTI patients
[4, 6, 7]. However, the general indications for
obtaining blood cultures in SSTIs remain poorly
defined. The high morbidity and mortality
associated with MRSA bacteremia underscore
the need to accurately identify patients who are
at increased risk for this complication. On the
other hand, indiscriminate blood culture col-
lection has significant financial and human
resource implications and results in unnecessary
venipuncture [8]. Cultures that grow contami-
nants may result in unnecessary antimicrobial
therapy, hospital admission, and extra testing
and monitoring [9, 10]. Several investigators
have identified risk factors for bacteremia in
patients with SSTI caused by a range of patho-
gens [7, 11, 12]; however no studies, to our
knowledge, have focused specifically on risk
factors for MRSA bacteremia in patients with
CO-MRSA SSTI. To address this knowledge gap,
we sought to determine sociodemographic and
clinical characteristics associated with MRSA
bacteremia in patients with CO-MRSA SSTI
residing in the metropolitan Detroit area. We
further sought to develop and validate a clinical
decision rule to predict the probability of MRSA
bacteremia based on characteristics readily
assessable at the time of initial presentation in
the emergency department (ED). This clinical
tool will be particularly valuable as we enter the
era of rapid diagnostics, which are capable of
identifying the SSTI causative pathogen at the
patient bedside.
METHODS
Study Design and Setting
A retrospective, case-control design was utilized
for derivation of the clinical decision rule and
an internal temporal cohort was used for vali-
dation. Both cohorts were selected from two
academic medical centers servicing an urban
population: the Detroit Medical Center and the
Henry Ford Hospital. This study was performed
in accordance with the Helsinki Declaration of
1964 and its later amendments. Approval was
obtained from the Wayne State University
(#012918MP4E) and Henry Ford Hospital
(#12302) institutional review boards and the
Detroit Medical Center Research Committee
(#15594) with a waiver for informed consent.
Case Ascertainment
The population of interest included adult
patients (C 18 years) who satisfied all of the
following criteria: (1) admitted to inpatient
services through the ED between May 2010 and
May 2018; (2) International Classification of
Diseases, Ninth/Tenth Revision, Clinical Modi-
fication (ICD-9/10-CM), primary diagnosis code
for SSTI (abscess, cellulitis or wound infection);
(3) at least three of the following signs/symp-
toms: local pain/tenderness, swelling, ery-
thema, warmth, discharge, or tenderness; (4)
MRSA-positive culture from skin/skin structure
collected within 48 h of admission; (5) blood
culture collected within 48 h of admission.
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Patients discharged directly from the ED were
excluded. Blood cultures were ordered at the
discretion of the treating physician, and no
formal institutional guidelines were in place
during the study period to guide this decision.
In the derivation cohort, a case was defined
as any patient who met the above criteria and
had MRSA isolated from the index blood culture
for which SSTI was the suspected primary
source. Patients meeting the above criteria with
negative blood cultures or blood cultures
deemed contaminated by the clinical microbi-
ology laboratory served as development cohort
controls. Exclusion criteria included polymi-
crobial bacteremia, surgical-site infections,
amputations, decubitus ulcers, medical device-
associated SSTIs, necrotizing fasciitis,
osteomyelitis, septic arthritis and burns.
Patients with immunocompromising condi-
tions (hematologic malignancy; prior solid
organ or bone marrow transplant; cytotoxic
chemotherapy, biologic agent or antirejection
agent within 30 days; functional or surgical
splenectomy; HIV/AIDS; absolute neutrophil
count\500; chronic use of systemic corticos-
teroids equivalent to C prednisone 20 mg/day
C 2 weeks) were also excluded because these
patients typically have a higher likelihood of
poor outcomes, which demands more extensive
diagnostic and aggressive management approa-
ches irrespective of bacteremia risk [2, 13, 14].
Study patients were identified using the
clinical decision support system, Theradoc
(Premier Inc., Charlotte, NC, USA). A query was
submitted to identify cases with both blood and
skin specimen cultures positive for MRSA dur-
ing the study period. A separate query was
submitted to identify controls with MRSA skin
specimen cultures. For the derivation cohort,
the electronic medical record (EMR) of all con-
secutive patients meeting case criteria admitted
between May 2010 and August 2016 was
reviewed, whereas a random sample of patients
meeting control criteria admitted during the
same period was selected with the aim of
including one control for every case. The vali-
dation cohort consisted of all eligible patients
(MRSA SSTI ± bacteremia) admitted between
September 2016 and May 2018 to allow for
estimation of bacteremia prevalence and pre-
dictive values of the clinical decision rule.
Sample Size Calculation
Abnormal vital signs have been most consis-
tently associated with bacteremia in previous
studies examining risk factors in SSTI due to a
range of bacterial etiologies [7, 12, 15]. Thus, a
derivation sample size of 152 cases and 152
controls was required to achieve 80% power at
the 0.05 significance level to detect an odds
ratio of two or greater for a risk factor with a
prevalence of 25% in controls.
Data Management
Relevant patient demographic, laboratory and
clinical data were extracted from the EMR ret-
rospectively using a structured data collection
form and entered into REDCap (Research Elec-
tronic Data Capture, Vanderbilt University), an
electronic data capture tool hosted at Wayne
State University [16]. For each vital sign and
laboratory value, the most abnormal value
obtained within 24 h of admission was extrac-
ted. Comorbidity burden was quantified by
calculating the Charlson Comorbidity index
[17]. Acute kidney injury (AKI) was defined as
an increase in serum creatinine by 1.5 fold or
0.3 mg/dl from baseline [18]. Median household
income was derived using the US Census Bureau
2012–2016 American Community Survey Esti-
mates by zip code [19].
Data Analysis and Clinical Decision Rule
Development
Baseline characteristics were evaluated using
descriptive statistics. Categorical variables were
compared between cases and controls using
Pearson’s chi-squared or Fisher’s exact test.
Continuous and ordinal variables were com-
pared using the Student t test and Mann-Whit-
ney U test, as appropriate. Because of the
unequal proportions of bacteremic patients in
the derivation (1:1 matching) and validation
(true prevalence) cohorts, statistical
Infect Dis Ther (2019) 8:229–242 231
comparisons between the two cohorts are not
presented.
To identify independent risk factors for bac-
teremia, candidate variables with a P value\0.1
and with biologic plausibility for bacteremia in
the univariate analysis were entered into a
multivariable logistic regression model and
retained in the final model if the adjusted
P value was \ 0.05 using the Wald test and
individually if they were retained in C 95% of
1000 bootstrap samples with replacement. To
develop a parsimonious model that could be
used to derive a user-friendly clinical decision
rule, the number of independent predictors
considered for model entry was limited to ten.
Model fit was assessed with the Hos-
mer–Lemeshow goodness-of-fit test with non-
significant results considered adequate.
The clinical decision rule was derived using a
regression coefficient-based scoring method in
which independent predictive variables from
the regression model were assigned a weighted
value using the beta coefficients to reflect pre-
dictive power [20, 21]. Beta coefficients were
adjusted for potential overfitting by applying a
shrinkage factor [22]. Shrunken coefficients
were divided by 0.3 and rounded to the nearest
whole number [21, 23]. The area under the
receiver-operating characteristic curve (AUROC)
was used to quantify the decision score’s dis-
criminative ability; an AUROC value of 0.5
denotes random predictions and a value of 1
denotes perfect discrimination. Classification
and regression tree (CART) analysis were used to
derive homogeneous bacteremia risk groups
[24]. The performance characteristics of the
score at CART-derived thresholds was evaluated
by calculating the sensitivity and specificity
and, for the validation cohort, the positive and
negative predictive values. Statistical analyses
were conducted using SPSS, version 24 (IBM
Corp., Armonk, NY).
RESULTS
The derivation cohort consisted of 155 case
patients matched to a random sample of 152
control patients from a pool of 5876 patients
with a positive MRSA skin specimen culture.
The blood culture contamination rate in control
patients was 4.6%. Overall, the mean age was
48.1 (± 17.5) years with a male and African
American predominance (61.2% and 59.3%,
respectively). The majority of patients (65.1%)
were overweight or obese [body mass index
(BMI) C 25 kg/m2]. Over one-third (36.5%) were
considered to have a household income below
the federal poverty level, and 19.9% of patients
had no medical insurance. The median Charl-
son Comorbidity Index was 2 [interquartile
range (IQR) 0, 4]. Nearly one-third (30.3%) of
patients had a pre-existing diagnosis of diabetes
mellitus, while 18.2% were injection drug users
(IVDU). A substantial minority of patients had
been hospitalized within the previous 6 months
(20.5%), although\ 10% had a recent (60-day)
history of SSTI or MRSA infection.
The most frequent type of SSTI was abscess
(76.5%), and the lower extremity was the pre-
dominant site of infection (41.7%). Most
patients presented with leukocytosis (59.3%)
and 34.2% had an abnormal temperature.
As shown in Table 1, several demographic
and clinical characteristics distinguished case
and control patients. Bacteremic patients were
significantly older, less likely to be overweight
or obese, carried a higher burden of most
comorbidities, had a higher rate of recent hos-
pitalization and more often resided in a zip code
area with a median household income below
the federal poverty level. Case patients also
presented to the ED sooner after symptom onset
and had higher rates of abnormal vital signs and
laboratory measures (Table 1). Purulent celluli-
tis and infections localized to the head and neck
regions were significantly more common
among case patients, whereas upper extremity
infections were less often seen.
Table 2 displays the final parsimonious
multivariable logistic regression model. A total
of eight independent predictors for MRSA bac-
teremia were found; in descending order of
their adjusted odds ratios, they were: purulent
cellulitis, abnormal temperature, IVDU, leuko-
cytosis, tachycardia, AKI, BMI\ 25 kg/m2 and
non-upper extremity infection site. The AUROC
of the final model was 0.859 (95% CI 0.818,
0.901) (Fig. 1).
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Table 1 Derivation cohort baseline characteristics
Control
(MRSA SSI)
n = 152
Case
(MRSA SSI 1 bacteremia)
n = 155
P value
Age, years, mean (SD) 45.2 (15.8) 51.0 (18.6) 0.003
Male gender, n (%) 87 (57.2) 101 (65.2) 0.154
African American race, n (%) 85 (55.9) 97 (62.6) 0.235
BMI (kg/m2), median (IQR) 28.99 (24.44, 35.89) 26.89 (23.20, 34.01) 0.121
Overweight or obese (BMI C 25 kg/m2), n (%) 110 (72.4) 90 (58.1) 0.009
Annual household income level, n (%)a
Poverty 47 (30.9) 65 (41.9) 0.045
Low-moderate 52 (34.2) 55 (35.5) Reference
Middle-high 53 (34.9) 35 (22.6) 0.017
Medical insurance, n (%)
No insurance 27 (17.8) 34 (21.9) 0.360
Medicare 12 (7.9) 23 (14.8) 0.056
Medicaid 39 (25.7) 34 (21.9) 0.444
Private/mixed 74 (48.7) 64 (41.3) Reference
Comorbid conditions, n (%)
Hypertension 49 (32.2) 69 (44.5) 0.027
Diabetes mellitus 35 (23.0) 58 (37.4) 0.006
Chronic renal impairment 5 (3.3) 22 (14.2) 0.001
IV drug abuse 20 (13.2) 36 (23.2) 0.022
Charlson Comorbidity Index, median (IQR) 1 (0.3) 2 (2.5) \ 0.001
MDR risk factors, n (%)
Recent hospitalizationb 20 (13.2) 43 (27.7) 0.002
Recent antibiotic exposurec 13 (8.6) 16 (10.3) 0.596
Prior MRSA infectiond 7 (4.6) 13 (8.4) 0.179
Prior SSTId 12 (7.9) 18 (11.6) 0.273
Clinical presentatione, n (%)
T\ 35.6 C or[ 38 C 28 (18.4) 77 (49.7) \ 0.001
HR[ 100 beats/min 52 (34.2) 107 (69.0) \ 0.001
RR C 22 beats/min 18 (11.8) 43 (27.7) \ 0.001
SBP B 100 mmHg 26 (17.2) 46(29.7) 0.009
WBC[ 11 9 109/l 74 (48.7) 108 (69.7) \ 0.001
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The weighted coefficient-based bacteremia
risk score is also shown in Table 2. An individual
patient’s score is calculated by summing the
applicable points, with a higher score indicating
increased risk of bacteremia and total scores
ranging from 0 to 31. The discriminative ability
of the score was similar to the full multivariable
logistic regression model [bacteremia risk score
AUROC 0.848 (95% CI 0.806, 0.891)]. The per-
formance characteristics of the CART-derived
score thresholds are displayed in Table 3. A
score threshold of 6 points resulted in a sensi-
tivity and specificity of 98.71% (95% CI 95.42%,
99.84%) and 23.03% (95% CI 16.59%, 30.54%),
respectively. Two case patients had a risk score\
6: (1) an 18-year-old male with no significant
medical history, a temperature of 38.3 C (3
points) and a cutaneous abscess on the right
hand and (2) a previously healthy 37-year-old
female with no systemic signs and an abscess on
the lower left cheek (three points).
A total of 205 patients with MRSA skin/skin
structure specimens satisfied the inclusion and
exclusion criteria between 1 September 2016
and 15 May 2018 and were enrolled in the val-
idation cohort. Demographic and clinical char-
acteristics are displayed in Table 4. The
prevalence of MRSA bacteremia was 11.2%, and
the blood culture contamination rate was 4.4%.
The discriminative ability of the score in the
Table 1 continued
Control
(MRSA SSI)
n = 152
Case
(MRSA SSI 1 bacteremia)
n = 155
P value
AKIf 39 (25.7) 75 (48.4) \ 0.001
2 ? SIRS criteria 99 (65.1) 135 (87.1) \ 0.001
Days from symptom onset to ED visit
median (IQR)
5 (3.7) 3 (2.7) 0.029
SSTI type, n (%)
Abscess 140 (92.1) 95 (61.3) Reference
Purulent cellulitis 11 (7.2) 47 (30.3) \ 0.001
Wound infection 1 (0.7) 13 (8.4) 0.001
SSTI site, n (%)
Lower extremity 64 (42.1) 64 (41.3) Reference
Upper extremity 53 (34.9) 36 (23.2) 0.025
Trunk/torso 17 (11.2) 24 (15.5) 0.268
Head/neck 18 (11.8) 31 (20.0) 0.051
AKI acute kidney injury, BMI body mass index, ED emergency department, HR heart rate, IQR interquartile range, IV
intravenous, MDR multidrug-resistant, MRSA methicillin-resistant Staphylococcus aureus, n number, RR respiratory rate,
SBP systolic blood pressure, SD standard deviation, SIRS systemic inflammatory response syndrome, SSTI skin and soft
tissue infection, T temperature, WBC white blood cell count
a Derived using US Census data and zip code; poverty\ $24,250, low-moderate $24,251–$49,999, middle-high C 50,000
b Within 6 months
c Within 30 days
d Within 60 days
e Worst physiologic value within 24 h of initial presentation
f Increase in serum creatinine by 1.5 or 0.3 mg/dl from baseline
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validation cohort was AUROC 0.762; 95% CI
0.662, 0.862 (Fig. 2). As shown in Table 3, a
threshold score of 6 points maintained high
sensitivity (95.65%; 95% CI 78.05%, 99.89%)
and further demonstrated an excellent negative
predictive value (98.25%; 95% CI 89.05%,
99.74%). A clinical decision rule based on the
score threshold value of 6 is outlined in Table 5.
A blood culture is indicated by this rule for
patients with one major or at least two minor
criteria. Otherwise, patients are classified as low
risk and blood cultures may be omitted. As a
practical example, blood culture collection
would be indicated in a febrile patient present-
ing with a lower extremity cutaneous abscess by
this decision rule. Blood cultures would not be
indicated in an afebrile patient presenting with
lower extremity cutaneous abscess and no other
minor criteria.
DISCUSSION
To uncover findings that could assist clinicians
in making a rapid bedside assessment of MRSA
bacteremia risk in patients with CO-MRSA SSTI,
we identified eight independent risk factors
readily assessable at the time of initial
evaluation in the ED. A predictive scoring
model derived from these risk factors predicted
the likelihood of bacteremia in the derivation
and validation cohorts with high and moderate
discriminatory ability, respectively. However,
the evaluation of the clinical relevance of a
scoring system is based on not only the AUC
but also the clinical utility linked to that AUC.
The model accurately identifies patients at low
risk for bacteremia for whom blood cultures
may be safely omitted. If used in our patients
with CO-MRSA SSTI, the rule could appropri-
ately reduce blood cultures by approximately
28%. The clinical prediction rule may also be
used to identify patients at high risk for bac-
teremia. Patients in the validation cohort in the
highest CART-derived risk group (C 16 points)
had approximately three times the baseline
population risk of bacteremia (33.3% vs.
11.2%). A number of studies have demonstrated
the benefit of early appropriate antimicrobial
therapy for MRSA bacteremia [25, 26]; the pre-
diction rule could support early initiation of
more aggressive antimicrobial therapy for these
higher risk patients.
To our knowledge, this is the first clinical
scoring model developed specifically to deter-
mine MRSA bacteremia risk factors in CO-MRSA
Table 2 Final multivariable logistic regression model for bacteremia and risk score
Variable Unadjusted OR (95% CI) Adjusted OR
(95% CI)
P value b-Coefficienta Points
Purulent cellulitis 5.578 (2.763, 11.264) 8.449 (3.465, 20.603) \ 0.001 1.979 7
T\ 35.6 C or[ 38 C 4.372 (2.607, 7.332) 4.951 (2.571, 9.535) \ 0.001 1.482 5
IV drug abuse 1.997 (1.096, 3.639) 3.374 (1.517, 7.506) 0.003 1.127 4
WBC[ 11 9 109 /l 2.422 (1.518, 3.865) 2.769 (1.467, 5.224) 0.002 0.944 3
HR[ 100 beats/min 4.287 (2.659, 6.912) 2.719 (1.509, 4.899) 0.001 0.927 3
Acute kidney injury 2.716 (1.679, 4.396) 2.570 (1.345, 4.914) 0.004 0.875 3
BMI\ 25 kg/m2 1.892 (1.173, 3.050) 2.435 (1.251, 4.740) 0.009 0.825 3
Non-upper extremity infectionb 1.770 (1.073, 2.918) 2.165 (1.078, 4.348) 0.030 0.772 3
BMI body mass index, HR heart rate, IV intravenous, OR odds ratio, T temperature, WBC white blood cell count
a After applying shrinkage factor S = (model X2 - df)/model X2
b Includes lower extremity, head, neck, trunk, torso
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SSTI. The most recent iteration of the Infectious
Diseases Society of America (IDSA) Guidelines
for the management of SSTI suggest that, in
immunocompetent patients such as those
enrolled in the present study, blood cultures are
only indicated in those with cellulitis and sev-
ere systemic signs, specifically fever or
hypotension [2]. In our study, fever or
hypotension was absent in 43.3% of patients
with bacteremia, suggesting bacteremia may go
undetected in a large proportion of patients
using the IDSA criteria, possibly leading to
inappropriate treatment strategies. Conversely,
fever or hypotension was present in 27.3% of
patients in the absence of bacteremia, repre-
senting substantial healthcare resource waste.
Many of the risk factors identified in our
study, including abnormal vital signs, leukocy-
tosis and IVDU, are consistent with those
previously reported [7, 12, 15]. However, earlier
studies have included patients with SSTIs
because of the wide range of pathogens, and the
generalizability of results to patients with MRSA
SSTI was not clear [7, 12, 15]. Purulent cellulitis
was the most important risk factor in our
cohort. As these infections are characterized by
a diffuse spreading lesions with no defined foci
amendable to source control [2], this finding
should not be unexpected.
Prior studies have included patients with
high burdens of underlying comorbidities,
immunocompromising conditions and noso-
comial SSTI [7, 12, 15]. Our study is unique in
that it sought to determine risk factors for MRSA
bacteremia specifically in immunocompetent
adults with CO-SSTI for whom indications for
blood culture collection remain uncertain. Pre-
dictive models developed in these previous
Fig. 1 Multivariable logistic regression model and bac-
teremia risk score area under the receiver-operator curve:
derivation cohort (n = 307). Multivariable model
AUROC 0.859 (95% CI 0.818, 0.901). MRSA bacteremia
risk score AUROC 0.848 (95% CI 0.806, 0.891). Blue:
multivariable model. Green: MRSA bacteremia risk score
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studies have also included laboratory measures
not routinely collected in CO-SSTI patients (i.e.,
albumin, lactate and c-reactive protein)
[7, 12, 15], limiting practical utility in the ED.
We observed that bacteremic patients were
more likely to reside in areas of Detroit where
the median household income fell below the
federal poverty level on univariate analysis.
Many studies have found that persons living in
areas of lower socioeconomic status (SES) have
higher rates of MRSA colonization and infection
and, specifically, higher rates of invasive com-
munity-associated MRSA infection [27–29]. SES
may impact infectious disease rates and out-
comes through differences in living conditions,
comorbidities, heath literacy and behaviors
such as smoking and IVDU [29]. Interestingly,
we observed that bacteremic patients sought
care sooner after symptom onset, suggesting
that access to medical care was not a driver of
SES disparities. SES did not remain an indepen-
dent predictor in multivariable analysis, likely
because covariates included in our model may
also be on the causal pathway linking SES to
bacteremia. It is possible that the relationships
between other risk factors and SES differ in areas
outside of metropolitan Detroit, resulting in
alternative risk models. A broader understand-
ing of the mechanisms by which SES influences
complications in CO-MRSA SSTIs would be a
major step forward in developing strategies to
reduce the public health burden of SSTIs.
A notable finding of our study was that
excess weight appeared to have a protective
effect against progression to MRSA bacteremia.
Obesity is a well-described risk factor for MRSA
colonization and acquisition of a number of
infectious diseases including SSTIs [30, 31].
However, data are conflicting regarding whe-
ther this predisposition toward acquiring
infection also translates into worse outcomes in
patients who become infected [32–36]. A grow-
ing body of evidence now supports the ‘‘obesity
paradox,’’ the notion that, as observed in the
present study, obesity confers a protective effect
against complications in certain infections
[35–37]. One hypothesis is that that the chronic
inflammatory state associated with obesity may
actually lead to a heightened state of host
immune defense in certain infections [38].
Emerging evidence in S. aureus bacteremia has
uncovered the prognostic importance of a dys-
regulated immune response [39, 40]. Further
studies untangling the complex relationship
among bodyweight, host immune response and
outcomes are needed.
Our study has several important limitations
to consider. First, the differing case mix in the
development and validation cohorts meant that
we could not perform meaningful direct
Table 3 Performance of CART-derived risk score thresholds
Score Sensitivity (%)
(95% CI)
Specificity (%)
(95% CI)
Positive
predictive value
(%)
(95% CI)
Negative
predictive value
(%)
(95% CI)
Derivation
cohort
(n = 307)
Validation
cohort
(n = 205)
Derivation
cohort
(n = 307)
Validation
cohort
(n = 205)
Validation
cohort
(n = 205)
Validation
cohort
(n = 205)
C 6 98.71 (95.42,
99.84)
95.65 (78.05,
99.89)
23.03 (16.59,
30.54)
30.77 (24.15,
38.02)
14.86 (13.29,
16.59)
98.25 (89.05,
99.74),
C 12 77.42 (70.02,
83.74)
60.87 (38.54,
80.29)
78.95 (71.6,
85.13)
76.92 (70.11,
82.83)
25.0 (17.94,
33.69)
93.96 (90.28,
96.30)
C 16 45.16 (37.17,
53.35)
34.78 (16.38,
57.27)
95.39 (90.74,
98.13)
91.21 (86.12,
94.89)
33.33 (19.42,
50.91)
91.71 (89.11,
93.74)
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comparisons of baseline demographic and
clinical characteristics. However, our approach
enabled us to evaluate a larger number of risk
factors and perform more robust statistical
analysis while still obtaining an estimate of
blood culture positivity prevalence and the
Table 4 Validation cohort baseline characteristics
Characteristic n (%)
n = 205
Age, years, mean (SD) 43.53 (15.38)
Male gender, n (%) 111 (54.1)
African American race 126 (61.5)
BMI (kg/m2), median (IQR) 27.27 (23.06, 32.96)
Overweight or obese (BMI
C 25 kg/m2), n (%)
132 (64.4)
Annual household income level, n (%)a
Poverty 91 (44.4)
Low-moderate 77 (37.6)
Middle-high 32 (15.6)
Medical insurance, n (%)
No insurance 17 (8.3)
Medicare 18 (8.8)
Medicaid 48 (23.4)
Private/mixed 122 (59.5)
Comorbid conditions, n (%)
Hypertension 60 (29.3)
Diabetes mellitus 33 (16.1)
Chronic renal impairment 7 (3.4)
IV drug abuse 36 (17.6)
Charlson Comorbidity Index,
median (IQR)
1 (0, 2)
MDR risk factors, n (%)
Recent hospitalizationb 51 (24.9)
Recent antibiotic exposurec 31 (15.1)
Prior MRSA infectiond 5 (2.4)
Prior SSTI 18 (8.8)
Clinical presentatione, n (%)
T\ 35.6 C or[ 38 C 22 (10.7)
HR[ 100 beats/min 82 (40.0)
RR C 22 beats/min 27 (13.2)
SBP B 100 mmHg 44 (21.5)
Table 4 continued
Characteristic n (%)
n = 205
WBC[ 11 9 109/l 94 (45.9)
AKIf 25 (12.2)
2 ? SIRS criteria 131 (63.9)
Days from symptom onset to ED visit,
median (IQR)
4 (2.7)
SSTI type, n (%)
Abscess 153 (74.6)
Purulent cellulitis 35 (17.1)
Wound infection 17 (8.3)
SSTI site, n (%)
Lower extremity 72 (35.1)
Upper extremity 78 (38.0)
Trunk/torso 33 (16.1)
Head/neck 22 (10.7)
AKI acute kidney injury, BMI body mass index, ED
emergency department, HR heart rate, IQR interquartile
range, IV intravenous, MDR multidrug-resistant, MRSA
methicillin-resistant Staphylococcus aureus, n number, RR
respiratory rate, SBP systolic blood pressure, SD standard
deviation, SIRS systemic inflammatory response syndrome,
SSTI skin and soft tissue infection, T temperature, WBC
white blood cell count
a Derived using US Census data and zip code; poverty
\ $24,250, low-moderate $24,251–$49,999, middle-high
C 50,000
b Within 6 months
c Within 30 days
d Within 60 days
e Worst physiologic value within 24 h of initial
presentation
f Increase in serum creatinine by 1.5 fold or 0.3 mg/dl
from baseline
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potential impact of operationalizing our find-
ings. Second, the study is subject to the inher-
ent bias of its retrospective design. Blood
cultures were performed at the discretion of the
treating physician, and previous studies have
clearly demonstrated that physicians are more
inclined to order blood cultures in patients with
a more severe presentation [7, 12, 41]. Addi-
tionally, we focused on SSTIs severe enough to
require inpatient admission, and thus our find-
ings may not generalize to patients with CO-
SSTI managed in the outpatient setting.
Although MRSA is now the predominant
pathogen in purulent SSTIs in many regions, in
the absence of rapid diagnostics, the true cau-
sative pathogen is not known at the point when
blood cultures are ordered. Our data were
obtained from two medical centers serving a
predominantly inner city population of lower
Fig. 2 Multivariable logistic regression model and bac-
teremia risk score area under the receiver-operator curve:
validation cohort (n = 205). Multivariable model
AUROC 0.763 (95% CI 0.658, 0.868). MRSA bacteremia
risk score AUROC 0.762 (95% CI 0.662, 0.862). Blue:
multivariable model. Green: MRSA bacteremia risk score
Table 5 Proposed blood culture decision rule in patients
with MRSA SSTI
Major criterion Minor criteria
Purulent cellulitis History of IV drug use
BMI\ 25 kg/m2
Non-upper extremity infection site
Acute kidney injury
Temperature\ 35.6 C or[ 38 C
WBC[ 11 9 109/l
Heart rate[ 100 beats/min
Blood cultures should be strongly considered in patients
with 1 major criterion or C 2 minor criteria
BMI body mass index, IV intravenous, WBC white blood
cell count
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socioeconomic status and may not be general-
izable to other institutions in distinct geo-
graphic areas or serving a different patient
population by sociodemographic factors. Vali-
dation in other populations is necessary before
widespread clinical use. Finally, infection man-
agement decisions are complex activities
requiring the clinician to weigh a number of
competing risks and benefits based on the
probabilities of disease and the quality of data
available. The decision rule developed by our
group is an attractive strategy to assist in this
decision-making process but should never
supersede clinical judgment.
CONCLUSION
Based on demographic and clinical characteris-
tics, the decision rule developed and validated
in this study provides a practical tool to stratify
patients with CO-MRSA SSTI based on bac-
teremia risk and assist in clinical decision-mak-
ing pertaining to the utility of blood cultures.
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